Objectives and methods

Medical Scientific Liaisons (MSLs) are essential assets for the pharma company. MSLs are scientific experts in a therapeutic area, and their role is to link industry and doctors to disseminate scientific information and gather insights on unmet medical needs. Their role is quite different from others in the industry because based on quality more than quantity; therefore, there still needs to be an evaluation method able to capture in full the potential of the role. This results in MSLs needing to feel more valued and the industry needing to demonstrate the value that MSLs bring to the company. 

This work aimed to collect all the information available in the literature on metrics and Key Performance Indicators (KPIs) currently used for MSL's evaluation. To achieve that, I collected data from trusted and specialized papers, using PubMed as the central database. An interesting factor is the scarcity of published material on the issue, even if the topic is considered central for both industry and MSLs.

I also had some interviews with experts in the field. Their contributions were precious because they helped me fill the literature's lack of data. 

Collecting all the information available helped me better understand the role of the MSL and clearly showed that the current metric system can be improved.

1. Morgan DK, Domann DE, Collins GE, Massey KL, Moss RJ. History and Evolution of Field-Based Medical Programs. Drug Information Journal. 2000;34(4):1049-1052. doi:10.1177/009286150003400408
2. Gupta S, Nayak R. An insight into the emerging role of regional medical advisor in the pharmaceutical industry. Perspectives in Clinical Research. 2013;4(3):186. doi:10.4103/2229-3485.115386
3. Rutherford P, Smith N. Medical Science Liaisons: A Key to Driving Patient Access to New Therapies. https://www.iqvia.com/-/media/library/white-papers/medical-science-liaisons.pdf
4. Erin, saas C. The Medical Science Liaison: An a to Z Guide, Second Edition.; 2011.
5. Medical Science Liaison Guidelines – Medical Science Liaison Society. MSL Society. Accessed July 28th, 2022. https://www.themsls.org/msl-guidelines/
6. Bengtsson T, Scott K. Population Aging and the Future of the Welfare State: The Example of Sweden. Population and Development Review. 2011;37:158-170. doi:10.1111/j.1728-4457.2011.00382.x
7. Gusmano MK, Okma KGH. Population Aging and the Sustainability of the Welfare State. Hastings Center Report. 2018;48:S57-S61. doi:10.1002/hast.915
8. OTCOMES_ GUIDANCE FOR CLINICAL TRIAL PROTOCOLS. SPIRIT. https://www.spirit-statement.org/outcomes-2/
9. Gray NH. MSL Roles & Goals. Pharma marketing news.
10. Codice deontologico – Farmindustria. https://www.farmindustria.it/documenticategory/codice-deontologico/
11. The EFPIA Code. Efpia. Eu. Published 2019. https://www.efpia.eu/relationships-code/the-efpia-code/
12. Open Payments | CMS. www.cms.gov. https://www.cms.gov/OpenPayments
13. Theron P, Britland M, Holder D, Ikeda Y, Rewers RF, Tiku A. Promoting Best Practices for Medical Science Liaisons Position Statement from the APPA, IFAPP, MAPS, and MSLS. Therapeutic Innovation & Regulatory Science. 2021;55(6):1139-1144. doi:10.1007/s43441-021-00310-y
14. Maeda H. Medical Affairs in Pharmaceutical Companies and Related Pharmaceutical Regulations in Japan. Frontiers in Medicine. 2021;8. doi:10.3389/fmed.2021.672095
15. Research C for D.E. and. Responding to Unsolicited Requests for Off-Label Information About Prescription Drugs and Medical Devices. U.S. Food and Drug Administration. Published February 1st, 2021. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/responding-unsolicited-requests-label-information-about-prescription-drugs-and-medical-devices
16. Ibrahim S. The relation between the tracking/reporting system for MSLs in medical affairs departments in pharmaceutical companies located within the MENA region and its impact on the MSL productivity. Journal of Medical Science And clinical Research. 2020;08(07). doi:10.18535/jmscr/v8i7.47
17. org. What is a Key Performance Indicator (KPI)? Kpi.org. Published 2019. https://kpi.org/KPI-Basics
18. Chin J. Executive Primer to Medical Science Liaison Metrics.; 2009.
19. Measuring MSL Value: Metrics that Matter - Pangaea Consultants. www.pangaea-consultants.com. Accessed October 23rd, 2022. https://www.pangaea-consultants.com/blog/measuring-msl-value-metrics-that-matter/
20. Sastre V, Matesanz-Marín A, García C, González del Castillo A. The medical science liaison role in Spain: A nationwide survey. Perspectives in Clinical Research. 2022;13(1):48. doi:10.4103/picr.picr_53_20
21. González del Castillo A, García C, Matesanz-Marín A, Gómez-Sánchez MJ, Sastre V. The Medical Science Liaison Role in Spain: A Survey About the Opinion of HealthCare Professionals. Therapeutic Innovation & Regulatory Science. 2021;56(1):96-103. doi:10.1007/s43441-021-00333-5
22. Saleem M, Cesario L, Wilcox L, et al. Evaluating Metrics Applied to the Medical Science Liaison (MSL) Role: A Survey-Based Study of Canadian MSL Leaders. Therapeutic Innovation & Regulatory Science. 2021;55(5):954-965. doi:10.1007/s43441-021-00291-y
23. Sperimentazione clinica dei farmaci. aifa.gov.it. Accessed December 8, 2022. https://www.aifa.gov.it/sperimentazione-clinica-dei-farmaci
24. The MSL Role in The Post-Pandemic Scenario: Lessons Learned and Future Prospects. THE MSL. Accessed December 15th, 2022. https://themsljournal.com/article/the-msl-role-in-the-post-pandemic-scenario-lessons-learned-and-future-prospects/
25. A "Slugging Percentage"​ Model to Cover All Bases of Medical Science Liaison (MSL) Performance Metrics! www.linkedin.com. Accessed December 19th, 2022. https://www.linkedin.com/pulse/slugging-percentage-model-cover-all-bases-medical-msl-mikhelashvili

Veronica Battaglia

Università Degli Studi Guglielmo Marconi